{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T04:42:56Z","timestamp":1784868176807,"version":"3.55.0"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T00:00:00Z","timestamp":1770422400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"vor","delay-in-days":59,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004047","name":"Karolinska Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Patient Rep Outcomes"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>EQ-5D-3L is a generic health-related quality of life (HRQoL) instrument, widely used in both economic and non-economic research. The purpose of this study is to examine the construct validity and responsiveness of EQ-5D-3L (descriptive system and EQ-5D-3L index), as well as EQ VAS in patients with ankylosing spondylitis (AS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methodology<\/jats:title>\n                    <jats:p>The study is based on real-world individual-level data from the Swedish Rheumatology Quality Register. To assess construct validity and responsiveness, we formulated and tested hypotheses concerning expected correlations between EQ-5D-3L and EQ VAS scores and those of comparator instruments (Bath Ankylosing Spondylitis Disease Activity Index, Ankylosing Spondylitis Disease Activity Score, Bath Ankylosing Spondylitis Functional Index, visual analogue scale for pain, fatigue, and general health), as well as expected differences between patient groups stratified by disease activity or physical function. Further, the area under the receiver operating characteristic curve was analysed. At least 75% of the predetermined hypotheses had to be confirmed to support construct validity or responsiveness.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In total, 4,878 patients with AS were included in this study. As expected, the correlations between EQ-5D-3L and EQ VAS scores and those from the comparator instruments were moderate or strong. Further, EQ-5D-3L and EQ VAS were able to detect expected differences between groups. Changes in EQ VAS over time also showed moderate to strong correlations with corresponding changes in comparator instruments. However, the changes in the EQ-5D-3L dimensions self-care and usual activities had weaker correlations than expected with changes in the comparator instruments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Over 75% of the hypotheses for construct validity of EQ-5D-3L and EQ VAS were confirmed, supporting their construct validity in patients with AS. Responsiveness of EQ VAS was also supported. However, limited responsiveness of the dimensions in the EQ-5D-3L indicates that the descriptive system and the EQ-5D-3L index may not fully capture changes over time among patients with AS.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s41687-026-01009-0","type":"journal-article","created":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T04:15:59Z","timestamp":1770437759000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The value of EQ-5D-3L and EQ VAS as a patient-reported outcome measure for patients with ankylosing spondylitis in routine healthcare: an evaluation of construct validity and responsiveness based on the Swedish Rheumatology Quality Register"],"prefix":"10.1186","volume":"10","author":[{"given":"Kinza","family":"Degerlund-Maldi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malin","family":"Regardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"Nystrand L\u00e4nsman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena","family":"Larsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Parodis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emelie","family":"Heintz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,7]]},"reference":[{"key":"1009_CR1","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1016\/s0140-6736(07)60635-7","volume":"369","author":"J Braun","year":"2007","unstructured":"Braun J, Sieper J, Ankylosing spondylitis (2007) Lancet 369:1379\u20131390. https:\/\/doi.org\/10.1016\/s0140-6736(07)60635-7","journal-title":"Lancet"},{"key":"1009_CR2","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1586\/14737167.2014.957679","volume":"14","author":"K Kotsis","year":"2014","unstructured":"Kotsis K, Voulgari PV, Drosos AA, Carvalho AF, Hyphantis T (2014) Health-related quality of life in patients with ankylosing spondylitis: a comprehensive review. Expert Rev Pharmacoecon Outcomes Res 14:857\u2013872. https:\/\/doi.org\/10.1586\/14737167.2014.957679","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"1009_CR3","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s00296-018-4180-4","volume":"39","author":"K Kr\u00fcger","year":"2019","unstructured":"Kr\u00fcger K, Burmester GR, Wassenberg S, Bohl-B\u00fchler M, Thomas MH (2019) Patient-reported outcomes with golimumab in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: non-interventional study GO-NICE in Germany. Rheumatol Int 39:131\u2013140. https:\/\/doi.org\/10.1007\/s00296-018-4180-4","journal-title":"Rheumatol Int"},{"key":"1009_CR4","doi-asserted-by":"publisher","first-page":"151996","DOI":"10.1016\/j.semarthrit.2022.151996","volume":"54","author":"A Ho","year":"2022","unstructured":"Ho A, Younis I, Le QA (2022) Impact of biologics on health-related quality of life in patients with ankylosing spondylitis: A systematic review and meta-analysis of randomized controlled trials. Semin Arthritis Rheum 54:151996. https:\/\/doi.org\/10.1016\/j.semarthrit.2022.151996","journal-title":"Semin Arthritis Rheum"},{"key":"1009_CR5","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.2165\/11596490-000000000-00000","volume":"30","author":"C Gaujoux-Viala","year":"2012","unstructured":"Gaujoux-Viala C, Fautrel B (2012) Cost effectiveness of therapeutic interventions in ankylosing spondylitis. PharmacoEconomics 30:1145\u20131156. https:\/\/doi.org\/10.2165\/11596490-000000000-00000","journal-title":"PharmacoEconomics"},{"key":"1009_CR6","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/0168-8510(96)00822-6","volume":"37","author":"R Brooks","year":"1996","unstructured":"Brooks R (1996) EuroQol: the current state of play. Health Policy Amst Neth 37:53\u201372. https:\/\/doi.org\/10.1016\/0168-8510(96)00822-6","journal-title":"Health Policy Amst Neth"},{"key":"1009_CR7","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","volume":"16","author":"EuroQol Group","year":"1990","unstructured":"EuroQol Group (1990) EuroQol\u2013a new facility for the measurement of health-related quality of life. Health Policy Amst Neth 16:199\u2013208. https:\/\/doi.org\/10.1016\/0168-8510(90)90421-9","journal-title":"Health Policy Amst Neth"},{"key":"1009_CR8","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s40258-017-0310-5","volume":"15","author":"NJ Devlin","year":"2017","unstructured":"Devlin NJ, Brooks R (2017) EQ-5D and the EuroQol group: Past, present and future. Appl Health Econ Health Policy 15:127\u2013137. https:\/\/doi.org\/10.1007\/s40258-017-0310-5","journal-title":"Appl Health Econ Health Policy"},{"key":"1009_CR9","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s40273-017-0545-x","volume":"35","author":"J Brazier","year":"2017","unstructured":"Brazier J, Ara R, Rowen D, Chevrou-Severac H (2017) A review of generic Preference-Based measures for use in Cost-Effectiveness models. PharmacoEconomics 35:21\u201331. https:\/\/doi.org\/10.1007\/s40273-017-0545-x","journal-title":"PharmacoEconomics"},{"key":"1009_CR10","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1007\/s10198-021-01411-z","volume":"23","author":"A Wang","year":"2022","unstructured":"Wang A, Rand K, Yang Z, Brooks R, Busschbach J (2022) The remarkably frequent use of EQ-5D in non-economic research. Eur J Health Econ 23:1007\u20131014. https:\/\/doi.org\/10.1007\/s10198-021-01411-z","journal-title":"Eur J Health Econ"},{"key":"1009_CR11","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s40273-014-0136-z","volume":"32","author":"T Wisl\u00f8ff","year":"2014","unstructured":"Wisl\u00f8ff T, Hagen G, Hamidi V, Movik E, Klemp M, Olsen JA (2014) Estimating QALY gains in applied studies: A review of Cost-Utility analyses published in 2010. PharmacoEconomics 32:367\u2013375. https:\/\/doi.org\/10.1007\/s40273-014-0136-z","journal-title":"PharmacoEconomics"},{"key":"1009_CR12","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s41687-020-00231-8","volume":"4","author":"O Ernstsson","year":"2020","unstructured":"Ernstsson O, Janssen MF, Heintz E (2020) Collection and use of EQ-5D for follow-up, decision-making, and quality improvement in health care - the case of the Swedish National quality registries. J Patient-Rep Outcomes 4:78. https:\/\/doi.org\/10.1186\/s41687-020-00231-8","journal-title":"J Patient-Rep Outcomes"},{"key":"1009_CR13","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3109\/07853890109002087","volume":"33","author":"R Rabin","year":"2001","unstructured":"Rabin R, de Charro F (2001) EQ-5D: a measure of health status from the EuroQol group. Ann Med 33:337\u2013343. https:\/\/doi.org\/10.3109\/07853890109002087","journal-title":"Ann Med"},{"key":"1009_CR14","doi-asserted-by":"publisher","first-page":"2711","DOI":"10.1007\/s11136-016-1345-z","volume":"25","author":"X Yang","year":"2016","unstructured":"Yang X, Fan D, Xia Q, Wang M, Zhang X, Li X et al (2016) The health-related quality of life of ankylosing spondylitis patients assessed by SF-36: a systematic review and meta-analysis. Qual Life Res 25:2711\u20132723. https:\/\/doi.org\/10.1007\/s11136-016-1345-z","journal-title":"Qual Life Res"},{"key":"1009_CR15","volume-title":"Using patient reported outcomes to improve health care","author":"J Appleby","year":"2016","unstructured":"Appleby J, Devlin N, Parkin D (2016) Using patient reported outcomes to improve health care. John Wiley & Sons, Incorporated, Newark, UNITED KINGDOM"},{"key":"1009_CR16","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1002\/hec.1608","volume":"19","author":"NJ Devlin","year":"2010","unstructured":"Devlin NJ, Parkin D, Browne J (2010) Patient-reported outcome measures in the NHS: new methods for analysing and reporting EQ-5D data. Health Econ 19:886\u2013905. https:\/\/doi.org\/10.1002\/hec.1608","journal-title":"Health Econ"},{"key":"1009_CR17","doi-asserted-by":"publisher","first-page":"2929","DOI":"10.1007\/s11136-024-03761-6","volume":"33","author":"LB Mokkink","year":"2024","unstructured":"Mokkink LB, Elsman EBM, Terwee CB (2024) COSMIN guideline for systematic reviews of patient-reported outcome measures version 2.0. Qual Life Res Int J Qual Life Asp Treat Care Rehabil 33:2929\u20132939. https:\/\/doi.org\/10.1007\/s11136-024-03761-6","journal-title":"Qual Life Res Int J Qual Life Asp Treat Care Rehabil"},{"key":"1009_CR18","volume-title":"Health measurement scales: A practical guide to their development and use","author":"DL Streiner","year":"2015","unstructured":"Streiner DL, Norman GR, Cairney J (2015) Health measurement scales: A practical guide to their development and use. Oxford University Press, Incorporated;, Oxford, UNITED KINGDOM"},{"key":"1009_CR19","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1007\/s11136-004-5681-z","volume":"14","author":"MH Kim","year":"2005","unstructured":"Kim MH, Cho YS, Uhm WS, Kim S, Bae SC (2005) Cross-cultural adaptation and validation of the Korean version of the EQ-5D in patients with rheumatic diseases. Qual Life Res 14:1401\u20131406. https:\/\/doi.org\/10.1007\/s11136-004-5681-z","journal-title":"Qual Life Res"},{"key":"1009_CR20","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1093\/rheumatology\/41.12.1380","volume":"41","author":"KL Haywood","year":"2002","unstructured":"Haywood KL, Garratt AM, Dziedzic K, Dawes PT (2002) Generic measures of health-related quality of life in ankylosing spondylitis: reliability, validity and responsiveness. Rheumatol Oxf 41:1380\u20131387. https:\/\/doi.org\/10.1093\/rheumatology\/41.12.1380","journal-title":"Rheumatol Oxf"},{"key":"1009_CR21","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1136\/ard.2006.060384","volume":"66","author":"A Boonen","year":"2007","unstructured":"Boonen A, van der Heijde D, ew\u00e9 R, van Tubergen A, Mielants H, Dougados M et al (2007) How do the EQ-5D, SF-6D and the well-being rating scale compare in patients with ankylosing spondylitis? Ann Rheum Dis 66:771\u2013777. https:\/\/doi.org\/10.1136\/ard.2006.060384","journal-title":"Ann Rheum Dis"},{"key":"1009_CR22","unstructured":"Svensk Reumatologis Kvalitetsregister (2025) Welcome to the Swedish Rheumatology Quality Register Health Professional. Sven Reumatol Kvalitetsregister n.d. https:\/\/srq.nu\/en\/welcome-health-professional\/"},{"key":"1009_CR23","unstructured":"Mokkink LB, Prinsen CA, Patrick DL, Alonso J, Bouter LM, de Vet HC et al (2019) COSMIN Study Design checklist for patient-reported outcome measurement instruments"},{"key":"1009_CR24","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jclinepi.2006.03.012","volume":"60","author":"CB Terwee","year":"2007","unstructured":"Terwee CB, Bot SD, de Boer MR, van der Windt DA, Knol DL, Dekker J et al (2007) Quality criteria were proposed for measurement properties of health status questionnaires. J Clin Epidemiol 60:34\u201342. https:\/\/doi.org\/10.1016\/j.jclinepi.2006.03.012","journal-title":"J Clin Epidemiol"},{"key":"1009_CR25","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1007\/s11136-018-1798-3","volume":"27","author":"CAC Prinsen","year":"2018","unstructured":"Prinsen CAC, Mokkink LB, Bouter LM, Alonso J, Patrick DL, de Vet HCW et al (2018) COSMIN guideline for systematic reviews of patient-reported outcome measures. Qual Life Res Int J Qual Life Asp Treat Care Rehabil 27:1147\u20131157. https:\/\/doi.org\/10.1007\/s11136-018-1798-3","journal-title":"Qual Life Res Int J Qual Life Asp Treat Care Rehabil"},{"key":"1009_CR26","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1097\/00005650-199711000-00002","volume":"35","author":"P Dolan","year":"1997","unstructured":"Dolan P (1997) Modeling valuations for EuroQol health States. Med Care 35:1095\u20131108. https:\/\/doi.org\/10.1097\/00005650-199711000-00002","journal-title":"Med Care"},{"key":"1009_CR27","unstructured":"Tandv\u00e5rds- och l\u00e4kemedelsf\u00f6rm\u00e5nsverket (2023) https:\/\/www.tlv.se\/download\/18.5115ffa918b6593374ce4bc\/1698307301974\/bes231019_dupixent_1171-2023_underlag.pdf (accessed December 19, 2025)"},{"key":"1009_CR28","unstructured":"Tandv\u00e5rds- och l\u00e4kemedelsf\u00f6rm\u00e5nsverket (2024) https:\/\/www.tlv.se\/download\/18.3af67bbe18d8293d56e3cb1d\/1707744651218\/bed240212_imjudo_4104-2022.pdf (accessed December 19, 2025)"},{"key":"1009_CR29","unstructured":"Larsson S (2015) De erfarenhetsbaserade EQ-5D vikterna i praktiken: TLVs perspektiv. Powerpoint presentation presented at: IHE Forum: Klinisk och ekonomisk evidens under ett l\u00e4kemedels livscykel \u2013 Hur kan vi m\u00f6jligg\u00f6ra tidigare tillg\u00e5ng till innovativa l\u00e4kemedel? Liding\u00f6"},{"key":"1009_CR30","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1093\/rheumatology\/38.9.878","volume":"38","author":"A Calin","year":"1999","unstructured":"Calin A, Nakache J-P, Gueguen A, Zeidler H, Mielants H, Dougados M (1999) Defining disease activity in ankylosing spondylitis: is a combination of variables (Bath ankylosing spondylitis disease activity Index) an appropriate. instrument? Rheumatol 38:878\u2013882. https:\/\/doi.org\/10.1093\/rheumatology\/38.9.878","journal-title":"instrument? Rheumatol"},{"key":"1009_CR31","first-page":"2286","volume":"21","author":"S Garrett","year":"1994","unstructured":"Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A (1994) A new approach to defining disease status in ankylosing spondylitis: the bath ankylosing spondylitis disease activity index. J Rheumatol 21:2286\u20132291","journal-title":"J Rheumatol"},{"key":"1009_CR32","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1136\/annrheumdis-2022-222747","volume":"82","author":"V Navarro-Comp\u00e1n","year":"2023","unstructured":"Navarro-Comp\u00e1n V, Boel A, Boonen A, Mease PJ, Dougados M, Kiltz U et al (2023) Instrument selection for the ASAS core outcome set for axial spondyloarthritis. Ann Rheum Dis 82:763\u2013772. https:\/\/doi.org\/10.1136\/annrheumdis-2022-222747","journal-title":"Ann Rheum Dis"},{"key":"1009_CR33","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1136\/ard.2008.094870","volume":"68","author":"C Lukas","year":"2009","unstructured":"Lukas C, Landew\u00e9 R, Sieper J, Dougados M, Davis J, Braun J et al (2009) Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis 68:18. https:\/\/doi.org\/10.1136\/ard.2008.094870","journal-title":"Ann Rheum Dis"},{"key":"1009_CR34","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1093\/rheumatology\/kes142","volume":"51","author":"D van der Heijde","year":"2012","unstructured":"van der Heijde D, Braun J, Dougados M, Sieper J, Pedersen R, Szumski A et al (2012) Sensitivity and discriminatory ability of the ankylosing spondylitis disease activity score in patients treated with etanercept or sulphasalazine in the ASCEND trial. Rheumatol Oxf 51:1894\u20131905. https:\/\/doi.org\/10.1093\/rheumatology\/kes142","journal-title":"Rheumatol Oxf"},{"key":"1009_CR35","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1007\/s10067-014-2729-5","volume":"33","author":"YL Au","year":"2014","unstructured":"Au YL, Wong WS, Mok MY, Chung HY, Chan E, Lau CS (2014) Disease activity assessment in ankylosing spondylitis in a Chinese cohort: BASDAI or ASDAS? Clin Rheumatol 33:1127\u20131134. https:\/\/doi.org\/10.1007\/s10067-014-2729-5","journal-title":"Clin Rheumatol"},{"key":"1009_CR36","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1007\/s00296-017-3814-2","volume":"37","author":"IFA Sellas","year":"2017","unstructured":"Sellas IFA, Juanola Roura X, Alonso Ruiz A, Rosas J, Medina Luezas J, Collantes Estevez E et al (2017) Clinical utility of the ASDAS index in comparison with BASDAI in patients with ankylosing spondylitis (Axis Study). Rheumatol Int 37:1817\u20131823. https:\/\/doi.org\/10.1007\/s00296-017-3814-2","journal-title":"Rheumatol Int"},{"key":"1009_CR37","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1093\/rheumatology\/41.11.1295","volume":"41","author":"KL Haywood","year":"2002","unstructured":"Haywood KL, Garratt AM, Jordan K, Dziedzic K, Dawes PT (2002) Disease-specific, patient\u2010assessed measures of health outcome in ankylosing spondylitis: reliability, validity and responsiveness. Rheumatology 41:1295\u20131302. https:\/\/doi.org\/10.1093\/rheumatology\/41.11.1295","journal-title":"Rheumatology"},{"key":"1009_CR38","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1136\/ard.2008.100826","volume":"68","author":"D van der Heijde","year":"2009","unstructured":"van der Heijde D, Lie E, Kvien TK, Sieper J, Van den Bosch F, Listing J et al (2009) ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis 68:1811\u20131818. https:\/\/doi.org\/10.1136\/ard.2008.100826","journal-title":"Ann Rheum Dis"},{"key":"1009_CR39","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1093\/rheumatology\/ker087","volume":"50","author":"M Xu","year":"2011","unstructured":"Xu M, Lin Z, Deng X, Li L, Wei Y, Liao Z et al (2011) The ankylosing spondylitis disease activity score is a highly discriminatory measure of disease activity and efficacy following tumour necrosis factor-\u03b1 inhibitor therapies in ankylosing spondylitis and undifferentiated spondyloarthropathies in China. Rheumatol Oxf 50:1466\u20131472. https:\/\/doi.org\/10.1093\/rheumatology\/ker087","journal-title":"Rheumatol Oxf"},{"key":"1009_CR40","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/j.1756-185X.2010.01537.x","volume":"13","author":"K Nas","year":"2010","unstructured":"Nas K, Yildirim K, Cevik R, Karatay S, Erdal A, Baysal O et al (2010) Discrimination ability of ASDAS estimating disease activity status in patients with ankylosing spondylitis. Int J Rheum Dis 13:240\u2013245. https:\/\/doi.org\/10.1111\/j.1756-185X.2010.01537.x","journal-title":"Int J Rheum Dis"},{"key":"1009_CR41","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1007\/s00296-014-3168-y","volume":"35","author":"E Kilic","year":"2015","unstructured":"Kilic E, Kilic G, Akgul O, Ozgocmen S (2015) Discriminant validity of the ankylosing spondylitis disease activity score (ASDAS) in patients with non-radiographic axial spondyloarthritis and ankylosing spondylitis: a cohort study. Rheumatol Int 35:981\u2013989. https:\/\/doi.org\/10.1007\/s00296-014-3168-y","journal-title":"Rheumatol Int"},{"key":"1009_CR42","doi-asserted-by":"publisher","first-page":"e001839","DOI":"10.1136\/rmdopen-2021-001839","volume":"7","author":"A Boel","year":"2021","unstructured":"Boel A, Navarro-Comp\u00e1n V, van der Heijde D (2021) Test\u2013retest reliability of outcome measures: data from three trials in radiographic and non-radiographic axial spondyloarthritis. RMD Open 7:e001839. https:\/\/doi.org\/10.1136\/rmdopen-2021-001839","journal-title":"RMD Open"},{"key":"1009_CR43","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1093\/rheumatology\/kev125","volume":"54","author":"A Van Tubergen","year":"2015","unstructured":"Van Tubergen A, Black PM, Coteur G (2015) Are patient-reported outcome instruments for ankylosing spondylitis fit for purpose for the axial spondyloarthritis patient? A qualitative and psychometric analysis. Rheumatol U K 54:1842\u20131851. https:\/\/doi.org\/10.1093\/rheumatology\/kev125","journal-title":"Rheumatol U K"},{"key":"1009_CR44","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1080\/03009749950155724-1","volume":"28","author":"A Waldner","year":"1999","unstructured":"Waldner A, Cronstedt H, Stenstr\u00f6m CH (1999) The Swedish version of the bath ankylosing spondylitis disease activity index. Reliability and validity. Scand J Rheumatol 28:10\u201316. https:\/\/doi.org\/10.1080\/03009749950155724-1","journal-title":"Scand J Rheumatol"},{"key":"1009_CR45","unstructured":"EULAR outcome measures library (2025) Ankylosing Spondylitis Disease Activity Score (ASDAS) n.d. https:\/\/oml.eular.org\/oml_search_results_details.cfm?id=31&action=All%20information"},{"key":"1009_CR46","first-page":"2281","volume":"21","author":"A Calin","year":"1994","unstructured":"Calin A, Garrett S, Whitelock H, Kennedy LG, O\u2019Hea J, Mallorie P et al (1994) A new approach to defining functional ability in ankylosing spondylitis: the development of the bath ankylosing spondylitis functional index. J Rheumatol 21:2281\u20132285","journal-title":"J Rheumatol"},{"key":"1009_CR47","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1093\/rheumatology\/keh549","volume":"44","author":"KL Haywood","year":"2005","unstructured":"Haywood KL, Garratt AM, Dawes PT (2005) Patient-assessed health in ankylosing spondylitis: a structured review. Rheumatol Oxf 44:577\u2013586. https:\/\/doi.org\/10.1093\/rheumatology\/keh549","journal-title":"Rheumatol Oxf"},{"key":"1009_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/030097499750042272","volume":"111","author":"H Cronstedt","year":"1999","unstructured":"Cronstedt H, Waldner A, Stenstr\u00f6m CH (1999) The Swedish version of the bath ankylosing spondylitis functional index. Reliability and validity. Scand J Rheumatol Suppl 111:1\u20139","journal-title":"Scand J Rheumatol Suppl"},{"key":"1009_CR49","unstructured":"Svensk Reumatologis Kvalitetsregister. BES\u00d6KSBLANKETT - Patient (2023) https:\/\/srq.nu\/wp-content\/uploads\/2023\/10\/Besoksblankett-alla-diagnoser.pdf (accessed July 31, 2025)"},{"key":"1009_CR50","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1586\/erp.11.9","volume":"11","author":"MT King","year":"2011","unstructured":"King MT (2011) A point of minimal important difference (MID): a critique of terminology and methods. Expert Rev Pharmacoecon Outcomes Res 11:171\u2013184. https:\/\/doi.org\/10.1586\/erp.11.9","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"1009_CR51","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.jval.2024.11.006","volume":"28","author":"F Al Sayah","year":"2025","unstructured":"Al Sayah F, Jin X, Short H, McClure NS, Ohinmaa A, Johnson JA (2025) A systematic literature review of important and meaningful differences in the EQ-5D index and visual analog scale scores. Value Health J Int Soc Pharmacoeconomics Outcomes Res 28:470\u2013476. https:\/\/doi.org\/10.1016\/j.jval.2024.11.006","journal-title":"Value Health J Int Soc Pharmacoeconomics Outcomes Res"},{"key":"1009_CR52","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1016\/j.socscimed.2004.08.034","volume":"60","author":"CA Marra","year":"2005","unstructured":"Marra CA, Woolcott JC, Kopec JA, Shojania K, Offer R, Brazier JE et al (2005) A comparison of generic, indirect utility measures (the HUI2, HUI3, SF-6D, and the EQ-5D) and disease-specific instruments (the RAQoL and the HAQ) in rheumatoid arthritis. Soc Sci Med 1982 60:1571\u20131582. https:\/\/doi.org\/10.1016\/j.socscimed.2004.08.034","journal-title":"Soc Sci Med 1982"},{"key":"1009_CR53","unstructured":"Campbell M, Machin D, Walters S (2007) Medical Statistics"},{"key":"1009_CR54","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1037\/a0024338","volume":"141","author":"CO Fritz","year":"2012","unstructured":"Fritz CO, Morris PE, Richler JJ (2012) Effect size estimates: current use, calculations, and interpretation. J Exp Psychol Gen 141:2\u201318. https:\/\/doi.org\/10.1037\/a0024338","journal-title":"J Exp Psychol Gen"},{"key":"1009_CR55","volume-title":"Research methods and statistics in psychology","author":"H Coolican","year":"2014","unstructured":"Coolican H (2014) Research methods and statistics in psychology, 6th edn. Psychology, New York, NY, US","edition":"6"},{"key":"1009_CR56","unstructured":"Svensk Reumatologisk F\u00f6rening (2022) https:\/\/svenskreumatologi.se\/wp-content\/uploads\/2023\/01\/riktlinjer-axial-spondylartrit-och-psoriasisartrit-220127.pdf (accessed May 8, 2024)"},{"key":"1009_CR57","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s11136-013-0496-4","volume":"23","author":"K Burstr\u00f6m","year":"2014","unstructured":"Burstr\u00f6m K, Sun S, Gerdtham U-G, Henriksson M, Johannesson M, Levin L-\u00c5 et al (2014) Swedish experience-based value sets for EQ-5D health States. Qual Life Res 23:431\u2013442. https:\/\/doi.org\/10.1007\/s11136-013-0496-4","journal-title":"Qual Life Res"},{"key":"1009_CR58","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1046\/j.1471-6712.2002.00067.x","volume":"16","author":"N Tamiya","year":"2002","unstructured":"Tamiya N, Araki S, Ohi G, Inagaki K, Urano N, Hirano W et al (2002) Assessment of pain, depression, and anxiety by visual analogue scale in Japanese women with rheumatoid arthritis. Scand J Caring Sci 16:137\u2013141. https:\/\/doi.org\/10.1046\/j.1471-6712.2002.00067.x","journal-title":"Scand J Caring Sci"},{"key":"1009_CR59","doi-asserted-by":"publisher","first-page":"e000140","DOI":"10.1136\/rmdopen-2015-000140","volume":"1","author":"M Sendlbeck","year":"2015","unstructured":"Sendlbeck M, Araujo EG, Schett G, Englbrecht M (2015) Psychometric properties of three single-item pain scales in patients with rheumatoid arthritis seen during routine clinical care: a comparative perspective on construct validity, reproducibility and internal responsiveness. RMD Open 1:e000140. https:\/\/doi.org\/10.1136\/rmdopen-2015-000140","journal-title":"RMD Open"},{"key":"1009_CR60","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1002\/art.22611","volume":"57","author":"S Hewlett","year":"2007","unstructured":"Hewlett S, Hehir M, Kirwan JR (2007) Measuring fatigue in rheumatoid arthritis: a systematic review of scales in use. Arthritis Rheum 57:429\u2013439. https:\/\/doi.org\/10.1002\/art.22611","journal-title":"Arthritis Rheum"},{"key":"1009_CR61","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1002\/art.1780300605","volume":"30","author":"LF Callahan","year":"1987","unstructured":"Callahan LF, Brooks RH, Summey JA, Pincus T (1987) Quantitative pain assessment for routine care of rheumatoid arthritis patients, using a pain scale based on activities of daily living and a visual analog pain scale. Arthritis Rheum 30:630\u2013636. https:\/\/doi.org\/10.1002\/art.1780300605","journal-title":"Arthritis Rheum"},{"key":"1009_CR62","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1185\/03007999909113372","volume":"15","author":"N Bellamy","year":"1999","unstructured":"Bellamy N, Campbell J, Syrotuik J (1999) Comparative study of Self-rating pain scales in rheumatoid arthritis patients. Curr Med Res Opin 15:121\u2013127. https:\/\/doi.org\/10.1185\/03007999909113372","journal-title":"Curr Med Res Opin"},{"key":"1009_CR63","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1136\/ard.59.12.966","volume":"59","author":"AC Verhoeven","year":"2000","unstructured":"Verhoeven AC, Boers M, van der Linden S (2000) Responsiveness of the core set, response criteria, and utilities in early rheumatoid arthritis. Ann Rheum Dis 59:966\u2013974. https:\/\/doi.org\/10.1136\/ard.59.12.966","journal-title":"Ann Rheum Dis"},{"key":"1009_CR64","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1002\/art.1780381108","volume":"38","author":"R Buchbinder","year":"1995","unstructured":"Buchbinder R, Bombardier C, Yeung M, Tugwell P (1995) Which outcome measures should be used in rheumatoid arthritis clinical trials? Clinical and quality-of-life measures\u2019 responsiveness to treatment in a randomized controlled trial. Arthritis Rheum 38:1568\u20131580. https:\/\/doi.org\/10.1002\/art.1780381108","journal-title":"Arthritis Rheum"},{"key":"1009_CR65","first-page":"610","volume":"35","author":"MM Veehof","year":"2008","unstructured":"Veehof MM, ten Klooster PM, Taal E, van Riel PLCM, van de Laar MAFJ (2008) Comparison of internal and external responsiveness of the generic medical outcome study short Form-36 (SF-36) with disease-specific measures in rheumatoid arthritis. J Rheumatol 35:610\u2013617","journal-title":"J Rheumatol"},{"key":"1009_CR66","doi-asserted-by":"publisher","first-page":"717","DOI":"10.3899\/jrheum.090764","volume":"37","author":"C Lati","year":"2010","unstructured":"Lati C, Guthrie LC, Ward MM (2010) Comparison of the construct validity and sensitivity to change of the visual analog scale and a modified rating scale as measures of patient global assessment in rheumatoid arthritis. J Rheumatol 37:717\u2013722. https:\/\/doi.org\/10.3899\/jrheum.090764","journal-title":"J Rheumatol"},{"key":"1009_CR67","doi-asserted-by":"publisher","first-page":"e0311798","DOI":"10.1371\/journal.pone.0311798","volume":"19","author":"Y Li","year":"2024","unstructured":"Li Y, Ma D, Yang L (2024) Experiences and perceptions of patients with ankylosing spondylitis: A systematic review and meta-synthesis of qualitative studies. PLoS ONE 19:e0311798. https:\/\/doi.org\/10.1371\/journal.pone.0311798","journal-title":"PLoS ONE"},{"key":"1009_CR68","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/j.jval.2024.02.018","volume":"27","author":"LJ Cheng","year":"2024","unstructured":"Cheng LJ, Pan T, Chen LA, Cheng JY, Mulhern B, Devlin N et al (2024) The ceiling effects of EQ-5D-3L and 5L in general population health surveys: A systematic review and Meta-Analysis. Value Health 27:986\u2013997. https:\/\/doi.org\/10.1016\/j.jval.2024.02.018","journal-title":"Value Health"},{"key":"1009_CR69","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s12955-023-02115-z","volume":"21","author":"FS Teni","year":"2023","unstructured":"Teni FS, Burstr\u00f6m K, Devlin N, Parkin D, Rolfson O (2023) Experience-based health state valuation using the EQ VAS: a register-based study of the EQ-5D-3L among nine patient groups in Sweden. Health Qual Life Outcomes 21:34. https:\/\/doi.org\/10.1186\/s12955-023-02115-z","journal-title":"Health Qual Life Outcomes"},{"key":"1009_CR70","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","volume":"20","author":"M Herdman","year":"2011","unstructured":"Herdman M, Gudex C, Lloyd A, Janssen MF, Kind P, Parkin D et al (2011) Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res 20:1727\u20131736. https:\/\/doi.org\/10.1007\/s11136-011-9903-x","journal-title":"Qual Life Res"},{"key":"1009_CR71","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1007\/s40258-025-00989-2","volume":"23","author":"NJ Devlin","year":"2025","unstructured":"Devlin NJ, Xie F, Slaap B, Stolk E (2025) Measuring and valuing health using EuroQol instruments: new developments 2025 and beyond. Appl Health Econ Health Policy 23:947\u2013960. https:\/\/doi.org\/10.1007\/s40258-025-00989-2","journal-title":"Appl Health Econ Health Policy"},{"key":"1009_CR72","doi-asserted-by":"publisher","unstructured":"Dewilde S, Janssen MF, Phillips G, Mulhern B, Rencz F (2025) Comparing psychometric properties of 6 of the 5-level and 3-level EQ-5D bolt-ons in a large, multinational, longitudinal general population sample. Value Health S1098301525025665. https:\/\/doi.org\/10.1016\/j.jval.2025.09.009","DOI":"10.1016\/j.jval.2025.09.009"}],"container-title":["Journal of Patient-Reported Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41687-026-01009-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-026-01009-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-026-01009-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:42:39Z","timestamp":1781631759000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s41687-026-01009-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,7]]},"references-count":72,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1009"],"URL":"https:\/\/doi.org\/10.1186\/s41687-026-01009-0","relation":{},"ISSN":["2509-8020"],"issn-type":[{"value":"2509-8020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,7]]},"assertion":[{"value":"19 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"K.D.M. is a member of the EuroQoL PhD Network. I.P. has received funding and honoraria from Amgen, AstraZeneca, Aurinia Pharmaceuticals, Elly Lilly and Company, Gilead Sciences, BMS, GlaxoSmithKline, Janssen Pharmaceuticals, Novartis, Otsuka Pharmaceutical, and F. Hoffmann-La Roche AG, and consulting fees from BMS, AstraZeneca, Novartis, Otsuka, Roche, and Amgen. E.H. has received funding from EuroQol Research Foundation and The Swedish Rheumatism Association. C.N.L. has received funding from The Swedish Rheumatism Association. L.L. and M.R. declared no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"51"}}